Interview with an Author: Dr. George Rodrigues

We recently had a chance to speak with Dr. George Rodrigues, primary author of “Integration of Stereotactic Ablative Radiotherapy in the Management of Pulmonary Metastases from Salivary Adenoid Cystic Carcinoma,” and a key contributor to the Cureus journal with several papers published thus far.

urlGeorge is a Clinician Scientist and Radiation Oncologist at the Lawson Health Research Institute and London Health Sciences Centre. He has consulted on and provides radiation treatment for patients with genitourinary and thoracic cancers as well as brain metastases since 2001, when he graduated from the University of Toronto Radiation Oncology Residency Program. He is also a former award-winning Residency Program Director and is the Chair of the Genitourinary Multidisciplinary Disease Site.

C: Tell us a bit about the research you published with us.

GR: In the context of a case report, we use the example of a woman with pulmonary metastases from parotid gland adenoid cystic carcinoma to illustrate the sequencing of stereotactic radiotherapy in the context of other treatment options such as surgery and ablative technologies. A brief review of the literature and discussion is included in the manuscript. The conclusion of the case report suggests that SABR can be an effective tool in conjunction with other techniques for the treatment of pulmonary metastases in ACC, however, its use should be ideally directed to tumors not amenable to other techniques (i.e. central lesions or high-risk surgical cases) given the limited safety data in using SABR for more than three pulmonary lesions.

C: What’s the one thing you’d want people to know if you only had 30 seconds to sum up your article?

GR: The main point of the case report was to highlight the fact that management of pulmonary metastases from head and neck adenoid cystic carcinoma can be complex. Multidisciplinary care is necessary to sequence surgical, radiation, and ablative therapies appropriately.

C: Where might you go from here and what’s next in your research?

GR: Not sure at this moment. The study of this patient population is very challenging given the rare nature of this disease entity. Prospective studies are generally absent in the literature. Perhaps population-based data can be used to further investigate hypotheses related to this interesting patient population.

C: How did you first hear about Cureus, and what persuaded you to submit to us?

GR: I first heard of Cureus from a colleague. I submit manuscripts to Cureus because of its open access nature, efficient peer review system and low cost.

C: Thanks for taking the time to chat with us and submitting another great article to Cureus!

Cureus Authors in the News: Dr. Laura Esserman’s I-SPY TRIAL

Dr. Laura Esserman, the principal investigator for the I-SPY adaptive studies and a contributing author to Cureus, has been working with Puma Biotechnology to assess neratinib for metastatic HER2-positive breast cancer. Why is this newsworthy, you say? Well, the I-SPY TRIAL is paving the way for accelerated regulatory review of new drug combinations, enabling potentially life-saving medicine to get to market faster than ever before.

This emphasis on accelerated efficiency and quality is similar to that of Cureus. We value speed and efficiency (although never at the expense of quality) in publishing important medical science and providing free access to this knowledge all across the world.

Many in the medical community have closely watched and waited for word on the study’s results, as the spotlight afforded by this research has shone brightly on both the I-SPY TRIAL and Dr. Esserman.

As a key contributor to Cureus, we couldn’t be prouder and more encouraged by these exciting developments made possible by all the hard work of Dr. Esserman and her team. And we’re not the only ones, as there has been plenty of positive media coverage as well, including this report on NBC Nightly News.

The good folks over at OncLive recently caught up with Dr. Esserman, and she had this to say regarding recent I-SPY 2 TRIAL:

If you’d like to learn more, there’s no better place to go than directly to the source – click here to check out the original journal article, A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents, only on Cureus.

Related articles